Inscripta, a US-based gene-editing technology developer that emerged out of University of Colorado, Boulder, closed a $55.5m series C round on Wednesday.
The round was co-led by Mérieux Développement, the investment arm of healthcare technology provider Institut Mérieux and VC firm Paladin Capital, while Venrock, Foresite, MLS Capital and NanoDimension also participated.
Founded in 2015 as Muse Biotechnology, Inscripta’s offering enables researchers to engineer cells by using a suite of gene-editing tools including instruments, reagents and software.